Brief: Durect Corporation Doses First European Patient In Phase 2B Study Of Larsucosterol In Severe Alcohol-Associated Hepatitis
01/03/2022 15:22
March 1 (Reuters) - DURECT Corp DRRX.O :
* DURECT CORPORATION DOSES FIRST EUROPEAN PATIENT IN PHASE
2B
AHFIRM STUDY OF LARSUCOSTEROL(DUR-928) IN SEVERE
ALCOHOL-ASSOCIATED HEPATITIS
Source text for Eikon: ID:nPn8D9XwRa
Further company coverage: DRRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DURECT
See all newsBrief: Bausch Health Completes Acquisition Of Durect Corporation, Expanding Late-Stage Liver Disease Portfolio
Durect Corp Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: Durect Bausch Health Extend Tender Offer Date To Aug 12 - SEC Filing
Durect Corp Expected To Post A Loss Of 12 Cents A Share: Earnings Preview
Durect Corp Reports Results For The Quarter Ended March 31: Earnings Summary